BJDX vs. SINT, OSAP, OSA, RSLS, MOTS, NMRD, DYNT, QNRX, INVO, and TNON
Should you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include Sintx Technologies (SINT), ProSomnus (OSAP), ProSomnus (OSA), ReShape Lifesciences (RSLS), Motus GI (MOTS), Nemaura Medical (NMRD), Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), INVO Bioscience (INVO), and Tenon Medical (TNON). These companies are all part of the "surgical & medical instruments" industry.
Bluejay Diagnostics (NASDAQ:BJDX) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
Sintx Technologies received 34 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 61.02% of users gave Sintx Technologies an outperform vote.
Bluejay Diagnostics has a net margin of 0.00% compared to Sintx Technologies' net margin of -314.39%. Sintx Technologies' return on equity of -67.12% beat Bluejay Diagnostics' return on equity.
In the previous week, Bluejay Diagnostics' average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score.
Sintx Technologies has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
Bluejay Diagnostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 47.0% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 0.8% of Sintx Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Sintx Technologies beats Bluejay Diagnostics on 8 of the 13 factors compared between the two stocks.
Get Bluejay Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bluejay Diagnostics Competitors List
Related Companies and Tools
